Read by QxMD icon Read

Prostate cancer Quality of life

Velda J Gonzalez, Susan McMillan, Elsa Pedro, Maribel Tirado-Gomez, Leorey N Saligan
OBJECTIVE: To examine the health related quality of life (HRQOL) experienced by 79 Puerto Rican adults during cancer treatments. METHODS: This study used a descriptive, cross-sectional design. Participants completed a demographics form and the Functional Assessment of Cancer Therapy-General QOL questionnaire (FACT-G). Descriptive statistics were generated. RESULTS: Participants were ages 28-78; most of the participants had breast (38.0%), prostate (14...
2018: Puerto Rico Health Sciences Journal
M G Carta, A Preti, H S Akiskal
Human population is increasing in immense cities with millions of inhabitants, in which life is expected to run 24 hours a day for seven days a week (24/7). Noise and light pollution are the most reported consequences, with a profound impact on sleep patterns and circadian biorhythms. Disruption of sleep and biorhythms has severe consequences on many metabolic pathways. Suppression of melatonin incretion at night and the subsequent effect on DNA methylation may increase the risk of prostate and breast cancer...
2018: Clinical Practice and Epidemiology in Mental Health: CP & EMH
Alicia K Morgans, Yu-Hui Chen, Christopher J Sweeney, David F Jarrard, Elizabeth R Plimack, Benjamin A Gartrell, Michael A Carducci, Maha Hussain, Jorge A Garcia, David Cella, Robert S DiPaola, Linda J Patrick-Miller
Purpose Chemohormonal therapy with docetaxel and androgen deprivation therapy (ADT+D) for metastatic hormone-sensitive prostate cancer improves overall survival as compared with androgen deprivation therapy (ADT) alone. We compared the quality of life (QOL) between patients with metastatic hormone-sensitive prostate cancer who were treated with ADT+D and those who were treated with ADT alone. Methods Men were randomly assigned to ADT+ D (six cycles) or to ADT alone. QOL was assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P), FACT-Taxane, Functional Assessment of Chronic Illness Therapy-Fatigue, and the Brief Pain Inventory at baseline and at 3, 6, 9, and 12 months...
March 9, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Eeva Harju, Anja Rantanen, Mika Helminen, Marja Kaunonen, Taina Isotalo, Päivi Åstedt-Kurki
AIMS AND OBJECTIVES: The aim of this study was to examine changes in the marital relationship six months after the diagnosis and the effects of these changes on the health-related quality of life (HRQoL) of the patients with prostate cancer and their spouses. BACKGROUND: There is limited knowledge on the impact of a diagnosis of prostate cancer on the marital relationship and HRQoL of patients and their spouses. DESIGN: Survey with longitudinal descriptive and comparative elements...
March 8, 2018: Journal of Clinical Nursing
Sam Egger, Suzanne Hughes, David P Smith, Suzanne Chambers, Clare Kahn, Annette Moxey, Dianne L O'Connell
OBJECTIVE: To assess whether the use of complementary and alternative medicines therapies (CAMs) for prostate cancer and/or its treatment side effects by long-term survivors is associated with selected socio-demographic, clinical, health-related quality-of-life (HRQOL) and/or psychological factors. DESIGN, SETTING AND PARTICIPANTS: The Prostate Cancer Care and Outcomes Study (PCOS) is a population-based cohort study of men with prostate cancer who were aged less than 70 years at diagnosis in New South Wales, Australia...
2018: PloS One
Marsha Schlenter, Vanessa Berneking, Barabara Krenkel, Felix M Mottaghy, Thomas-Alexander Vögeli, Michael J Eble, Michael Pinkawa
PURPOSE: To analyze clinical results and quality of life of patients with localized prostate cancer after irradiation of the prostate with an 18F-choline-PET/CT-based simultaneous integrated boost (SIB) in comparison to a control group without SIB. METHODS: A total of 134 patients underwent intensity-modulated radiotherapy from 2007-2010. All patients received a total dose of 76 Gy with 2 Gy fractions to the prostate; 67 patients received an additional SIB of 80 Gy...
March 6, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Pierre Graff, Daniel Portalez, Amélie Lusque, Thomas Brun, Richard Aziza, Jonathan Khalifa, Mathieu Roumiguié, Marie-Laure Quintyn Ranty, Thomas Filleron, Jean-Marc Bachaud, Bernard Malavaud
PURPOSE: Focal therapy of prostate cancer requires precise positioning of therapeutic agents within well-characterized index tumors (ITs). We assessed the feasibility of low-dose-rate ultrafocal brachytherapy. METHODS AND MATERIALS: The present study was an institutional review board-approved European Clinical Trials Database-registered phase II protocol. Patients referred (October 2013 to August 2016) for active surveillance (prostate-specific antigen <10 ng/mL, cT1c-cT2a, Gleason score on referring biopsy specimens ≤6 (3+3), ≤3 positive biopsy cores, ≤50% of cancer) were preselected...
February 2, 2018: International Journal of Radiation Oncology, Biology, Physics
Richard M Martin, Jenny L Donovan, Emma L Turner, Chris Metcalfe, Grace J Young, Eleanor I Walsh, J Athene Lane, Sian Noble, Steven E Oliver, Simon Evans, Jonathan A C Sterne, Peter Holding, Yoav Ben-Shlomo, Peter Brindle, Naomi J Williams, Elizabeth M Hill, Siaw Yein Ng, Jessica Toole, Marta K Tazewell, Laura J Hughes, Charlotte F Davies, Joanna C Thorn, Elizabeth Down, George Davey Smith, David E Neal, Freddie C Hamdy
Importance: Prostate cancer screening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment. Objective: To evaluate the effect of a single prostate-specific antigen (PSA) screening intervention and standardized diagnostic pathway on prostate cancer-specific mortality. Design, Setting, and Participants: The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) included 419 582 men aged 50 to 69 years and was conducted at 573 primary care practices across the United Kingdom...
March 6, 2018: JAMA: the Journal of the American Medical Association
Tsz Kin Lee, Darren M C Poon, Anthony C F Ng, Terrence Ho, Savitri Singh-Carlson, Michel Joffres, Gurpreet Oshan, Jagbir Kohli, Winkle Kwan
AIM: The expanded prostate cancer index composite (EPIC) is a widely adopted instrument for the quality of life of patients with prostate cancer. We aimed to create a Chinese version of EPIC to further research in the Chinese-speaking population. METHODS: A prototype was created by forward-backward translations and revisions. During cultural adaptation, 15 participants were interviewed after they had completed the prototype. A few issues highlighted included confusion related to the question format, subject non-familiarity with the Chinese term for "hot flashes," and the use of the Chinese term for "breast" as a strictly female body part...
March 2018: Asia-Pacific Journal of Clinical Oncology
Yohann Foucher, Marine Lorent, Philippe Tessier, Stéphane Supiot, Véronique Sébille, Etienne Dantan
BACKGROUND: Patients with prostate cancer (PC) may be ready to make trade-offs between their quantity and their quality of life. For instance, elderly patients may prefer the absence of treatment if it is associated with a low-risk of disease progression, compared to treatments aiming at preventing disease progression but with a substantial deterioration of their Health-Related Quality of Life (HRQoL). Therefore, it seems relevant to compare the treatments by considering both survival and HRQoL...
March 5, 2018: Health and Quality of Life Outcomes
Karen Steindorf, Martina E Schmidt, Philipp Zimmer
A growing number of literature reports positive effects of physical activity and exercise. These effects concern prevention, mortality and progress of cancer. Furthermore they show a reduction of disease- and treatment-specific side effects, which implies a better patients' quality of life. Evidence shows a decreased mortality risk in patients with physically active cancer of colon, breast, ovaries and prostate. Activity recommendations for patients with cancer do not differ from those for healthy persons...
March 2018: Deutsche Medizinische Wochenschrift
Johnny R Ramroop, Mark N Stein, Justin M Drake
Prostate cancer is the most common malignancy in men in the United States. While androgen deprivation therapy results in tumor responses initially, there is relapse and progression to metastatic castration-resistant prostate cancer. Currently, all prostate cancer patients receive essentially the same treatment, and there is a need for clinically applicable technologies to provide predictive biomarkers toward personalized therapies. Genomic analyses of tumors are used for clinical applications, but with a paucity of obvious driver mutations in metastatic castration-resistant prostate cancer, other applications, such as phosphoproteomics, may complement this approach...
2018: Frontiers in Oncology
Sangkyu Lee, Sarah Kerns, Harry Ostrer, Barry Rosenstein, Joseph O Deasy, Jung Hun Oh
PURPOSE: Late genitourinary (GU) toxicity after radiation therapy limits the quality of life of prostate cancer survivors; however, efforts to explain GU toxicity using patient and dose information have remained unsuccessful. We identified patients with a greater congenital GU toxicity risk by identifying and integrating patterns in genome-wide single nucleotide polymorphisms (SNPs). METHODS AND MATERIALS: We applied a preconditioned random forest regression method for predicting risk from the genome-wide data to combine the effects of multiple SNPs and overcome the statistical power limitations of single-SNP analysis...
January 31, 2018: International Journal of Radiation Oncology, Biology, Physics
Marie-Anne van Stam, Arwen H Pieterse, Henk G van der Poel, J L H Ruud Bosch, Corinne Tillier, Simon Horenblas, Neil K Aaronson
PURPOSE: The aims of this study were: (1) to describe preferred and experienced roles in treatment decision-making among patients with localized prostate cancer (PC); (2) to identify how often patients' experienced roles matched their preferred roles; and (3) to determine whether active involvement in decision-making regardless of role preferences, or concordance between preferred and experienced role is the strongest predictor of more favourable patient-reported outcomes. MATERIAL AND METHODS: In this prospective, multicenter, observational study we obtained serial questionnaire data from newly-diagnosed localized PC patients (cT1-cT2 or Gleason≤7, PSA≤20) (N=454)...
February 28, 2018: Journal of Urology
Niven Mehra, David Dolling, Semini Sumanasuriya, Rossitza Christova, Lorna Pope, Suzanne Carreira, George Seed, Wei Yuan, Jane Goodall, Emma Hall, Penny Flohr, Gunther Boysen, Diletta Bianchini, Oliver Sartor, Mario A Eisenberger, Karim Fizazi, Stephane Oudard, Mustapha Chadjaa, Sandrine Macé, Johann S de Bono
BACKGROUND: Noninvasive biomarkers are needed to guide metastatic castration-resistant prostate cancer (mCRPC) treatment. OBJECTIVE: To clinically qualify baseline and on-treatment cell-free DNA (cfDNA) concentrations as biomarkers of patient outcome following taxane chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: Blood for cfDNA analyses was prospectively collected from 571 mCRPC patients participating in two phase III clinical trials, FIRSTANA (NCT01308567) and PROSELICA (NCT01308580)...
February 27, 2018: European Urology
Deirdre M J Walsh, Todd G Morrison, Ronan J Conway, Eamonn Rogers, Francis J Sullivan, AnnMarie Groarke
Background: Post traumatic growth (PTG) can be defined as positive change following a traumatic event. The current conceptualization of PTG encompasses five main dimensions, however, there is no dimension which accounts for the distinct effect of a physical trauma on PTG. The purpose of the present research was to test the role of PTG, physical post traumatic growth (PPTG), resilience and mindfulness in predicting psychological and health related adjustment. Method: Ethical approval was obtained from relevant institutional ethics committees...
2018: Frontiers in Psychology
Carla Freiberger, Vanessa Berneking, Thomas-Alexander Vögeli, Ruth Kirschner-Hermanns, Michael J Eble, Michael Pinkawa
PURPOSE: The aim of this study was to evaluate quality-of-life changes up to 10 years following three different radiotherapy concepts. METHODS AND MATERIALS: In the years 2000-2003, 295 patients were treated with external beam radiotherapy (EBRT; n = 135; 70.2 Gy in 1.8 Gy fractions), low-dose-rate brachytherapy (LDR-BT with I-125; n = 94; 145 Gy), and high-dose-rate brachytherapy (HDR-BT with Ir-192; n = 66; 18 Gy in two fractions using 4-6 needles) as a boost to EBRT (50...
February 26, 2018: Brachytherapy
Loay Kassem, Kyrillus S Shohdy, Omar Abdel-Rahman
BACKGROUND: A major, yet precisely studied, shift has occurred in treatment of advanced hormone-sensitive prostate cancer (HSPC) by addition of docetaxel to androgen deprivation therapy (ADT) in the first-line. Recently, two landmark trials showed that abiraterone acetate (AA) can be an effective alternative along with ADT in the same setting. We implemented a network meta-analysis to compare safety and efficacy of both combinations. METHODS: PubMed database, ASCO and ESMO meeting library databases of all results published until June 2017 were searched using the keywords: "prostate cancer" AND "docetaxel" OR "abiraterone acetate"...
February 28, 2018: Current Medical Research and Opinion
Robert T Dess, Theresa P Devasia, Nima Aghdam, William C Jackson, Payal D Soni, Clayton P Smith, Amyre L Mitchell, Simeng Suy, Daniel A Hamstra, Shruti Jolly, Paul L Nguyen, Felix Y Feng, Matthew J Schipper, Ted A Skolarus, David C Miller, Daniela A Wittmann, Sean P Collins, Daniel E Spratt
PURPOSE: To report sexual health-related quality of life outcomes and utilization and efficacy of sexual aids in a contemporary cohort of patients treated for localized prostate cancer. PATIENTS AND METHODS: Between 2008 and 2013, 471 consecutive men with localized prostate cancer were treated on 2 institutional protocols (NCT01766492, NCT01618851) or on a prospective institutional registry with patient-reported health-related quality of life. All patients were treated with ultra-hypofractionated radiation therapy...
January 31, 2018: International Journal of Radiation Oncology, Biology, Physics
Lixin Song, Kaitlyn L Dunlap, Xianming Tan, Ronald C Chen, Matthew E Nielsen, Rebecca L Rabenberg, Josephine K Asafu-Adjei, Bridget F Koontz, Sarah A Birken, Laurel L Northouse, Deborah K Mayer
BACKGROUND: This project explores a new model of care that enhances survivorship care planning and promotes health for men with localized prostate cancer transitioning to posttreatment self-management. Survivorship care planning is important for patients with prostate cancer because of its high incidence rate in the United States, the frequent occurrence of treatment-related side effects, and reduced quality of life (QOL) for both men and their partners. A key component of comprehensive survivorship care planning is survivorship care plans (SCPs), documents that summarize cancer diagnosis, treatment, and plans for follow-up care...
February 26, 2018: JMIR Research Protocols
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"